Amadix

Based in Spain, Amadix develops advanced blood-based diagnostic tests to facilitate early cancer detection, including key products for lung, colorectal, and pancreatic cancers. Amadix, founded in 2010 in Valladolid, Spain, specializes in blood-based diagnostics for cancer. The company has received two funding rounds, with the most recent round on February 10, 2025, where it raised EUR 2. 00 mn led by CRB Inverbio and Inveready Asset Management.

CEO Rocio Arroyo leads the company towards expanding its innovative testing solutions in the healthcare sector. Amadix focuses on innovative blood-based diagnostic tests for early detection of various cancers. Their flagship products include DiagnoLung®, a minimally invasive lung cancer test in clinical validation; PreveCol®, a CE-marked blood test for early colorectal cancer with FDA Breakthrough Device designation; and PancreaDix®, targeting early diagnosis of pancreatic cancer, also under clinical validation. These tests are aimed at healthcare providers and specialized oncology clinics across Europe and other global markets.

In the most recent fiscal year of 2023, Amadix reported a revenue of EUR 21,978. 10 and an EBITDA of EUR 1,146,163. 10. Amadix plans to enhance its product lineup with new offerings expected to launch following ongoing R&D initiatives.

The company aims to expand its market presence in Europe and the US, leveraging EUR 15 mn raised in venture debt funding from the European Investment Bank in February 2025 to support these efforts. This funding will be directed towards advancing product development and strengthening their market position.